The global drug discovery market size was valued at USD 111.93 billion in 2025 and is projected to grow from USD 118.53 billion in 2026 to USD 187.43 billion by 2034 at a CAGR of 5.9% during the forecast period 2026-2034. North America dominated the drug discovery market with a market share of 42.5% in 2025.
Drug discovery is the systematic process of identifying and developing new molecules that exhibit therapeutic potential. It typically involves a combination of scientific research, screening of chemical compounds, and testing to identify compounds with potential therapeutic effects. This process includes stages such as target identification, lead compound discovery, preclinical testing, and ultimately, clinical trials, with the aim of developing safe and effective drugs for treating various diseases.
Download a Free Sample To learn more about this report,
A major factor driving drug discovery is the increasing prevalence of chronic diseases and unmet medical needs. As conditions like cancer, diabetes, and neurodegenerative disorders continue to rise globally, there is growing demand for innovative treatments. This growing demand propels pharmaceutical companies and research institutions to invest in new drug development, using advanced technologies such as artificial intelligence, genomics, and high-throughput screening to accelerate the discovery process and accelerate the commercialization of innovative therapies.
Rising Adoption of In Silico Drug Discovery
The rising adoption of in silico drug discovery is transforming the pharmaceutical industry by integrating artificial intelligence (AI), machine learning (ML), molecular modeling, virtual screening, and predictive analytics to accelerate and optimize drug discovery. These computational techniques enable researchers to simulate biological processes, identify promising therapeutic targets, and predict how drug candidates interact with specific proteins before laboratory testing. AI-powered platforms significantly reduce reliance on extensive physical experimentation, lowering research costs and shortening development timelines while improving candidate selection accuracy.
The partnership combines generative AI, automation, and Takeda's disease biology expertise to identify and optimize clinically differentiated drug candidates more efficiently. The collaboration highlights the growing industry shift toward AI-native drug discovery workflows that improve research productivity, reduce early-stage development timelines, and increase the probability of identifying promising therapeutic candidates.
Growing Role of Outsourcing
The growing role of outsourcing is reshaping the pharmaceutical landscape as companies increasingly collaborate with contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and specialized research partners to streamline research and development (R&D). Outsourcing provides access to specialized scientific expertise, advanced technologies, and global research infrastructure while reducing operational costs and accelerating discovery timelines. This enables pharmaceutical companies to focus on strategic activities such as clinical development, regulatory approvals, and commercialization.
Under the agreement, Relation Therapeutics will generate proprietary human cellular datasets and develop AI-based disease models to identify novel therapeutic targets, while GSK will utilize its drug development expertise to advance selected programs. The collaboration reflects the growing trend of pharmaceutical companies outsourcing specialized AI-driven discovery capabilities to external innovation partners, enabling faster target identification and more efficient R&D processes.
Integration of Omics Technologies
The integration of omics technologies, including genomics, proteomics, transcriptomics, and metabolomics, is revolutionizing drug discovery by providing deeper insights into biological systems and disease mechanisms. These technologies enable researchers to analyze complex biological data at multiple molecular levels, helping identify novel therapeutic targets, predict drug responses, and support precision medicine approaches. The integration of multi-omics data with artificial intelligence (AI) and advanced analytics is further improving target validation and accelerating the development of personalized therapies.
The collaboration combines Illumina's genomics expertise with Tempus' multimodal data platform to enhance drug target identification, optimize patient stratification, and support pharmaceutical partners in developing personalized therapies. Such partnerships demonstrate the growing role of omics technologies in improving drug discovery efficiency and clinical success rates.
Intellectual Property Issues
Intellectual property (IP) issues remain a significant challenge for the drug discovery market, affecting innovation, commercialization, and competitive positioning. Securing strong patent protection is essential for safeguarding novel drug candidates and enabling companies to recover substantial R&D investments. However, patent disputes, challenges to patent validity, exclusivity expirations, and lengthy litigation can delay product launches, increase legal expenses, and create uncertainty for innovators and investors.
The legal dispute centers on patent protection and market exclusivity for biologic therapies, highlighting the increasing complexity of intellectual property management in the pharmaceutical industry. Such litigation can divert financial and operational resources away from innovation while delaying broader patient access to new therapies.
Growing Investment in Research and Development
Growing investment in research and development (R&D) continues to create significant opportunities for the drug discovery market by accelerating innovation and enabling the development of next-generation therapeutics. Governments, pharmaceutical companies, biotechnology firms, and venture capital investors are increasing funding to support advanced research, precision medicine, and AI-enabled drug discovery platforms. These investments strengthen scientific capabilities, accelerate target identification, and improve the efficiency of preclinical and clinical development.
The investment is intended to support the development and manufacturing of innovative medicines while strengthening Lilly's long-term research infrastructure. Such large-scale investments enable the adoption of advanced technologies, including AI, automation, and high-throughput screening, helping pharmaceutical companies accelerate drug discovery, improve development success rates, and bring novel therapies to patients more efficiently.
High Clinical Failure Rates and Rising Development Costs
High clinical failure rates and escalating research and development (R&D) costs remain major challenges for the drug discovery market. Despite advances in artificial intelligence (AI), computational modeling, and high-throughput screening, many drug candidates fail during preclinical studies or clinical trials due to insufficient efficacy, unexpected toxicity, or safety concerns. The lengthy development process, coupled with stringent regulatory requirements, significantly increases financial risk and extends the time required to bring new therapies to market. These challenges are particularly burdensome for small and mid-sized biotechnology companies with limited financial resources.
The decision highlights the inherent uncertainty of drug development, where promising candidates may fail even in advanced stages despite substantial investments. Such setbacks result in considerable financial losses, delay the availability of innovative therapies, and emphasize the need for more predictive drug discovery technologies to improve clinical success rates.
Request Customizationto receive a tailored report.
The market is segmented into small-molecule drugs and biologic drugs. Small-molecule drugs dominated the global market, accounting for 61.8% of the market share, valued at USD 69.17 billion in 2025, owing to their well-established manufacturing processes, lower production costs, broad therapeutic applications, and widespread regulatory approvals. Small-molecule drugs continue to play a vital role in treating chronic and infectious diseases due to their oral bioavailability, ease of distribution, and extensive commercial availability.
However, biologic drugs are projected to register the fastest CAGR of 10.6% during the forecast period, driven by rapid advancements in biotechnology and increasing demand for targeted therapies. Biologics provide highly precise mechanisms of action, making them particularly effective for treating complex diseases such as cancer, autoimmune disorders, and genetic disorders. Regulatory agencies such as the U.S. FDA and the European Medicines Agency (EMA) continue to accelerate approvals for innovative biologic therapies, while pharmaceutical companies are significantly expanding investments in biologics research and development.
The market is segmented into high-throughput screening (HTS), bioinformatics & in-silico modelling, computational drug discovery & drug design, nanotechnology, and others. High-throughput screening (HTS) held the largest market share of 29.4%, reaching USD 32.91 billion in 2025, due to its ability to rapidly evaluate thousands of chemical compounds and identify promising drug candidates. HTS significantly accelerates early-stage drug discovery, improves research efficiency, and reduces development timelines, making it an indispensable technology for pharmaceutical and biotechnology companies.
Meanwhile, computational drug discovery & drug design is expected to witness the highest CAGR of 11.4% during the forecast period, supported by increasing adoption of artificial intelligence, machine learning, molecular modelling, and advanced computational platforms that improve target identification, lead optimization, and predictive drug design while lowering research costs.
Moreover, continuous advancements in HTS technologies continue to reinforce their widespread adoption. For instance, AstraZeneca's collaboration with Charles River Laboratories to integrate advanced high-throughput screening technologies into its drug discovery programs demonstrates the industry's commitment to accelerating pharmaceutical innovation.
The market is categorized into pharmaceutical companies, contract research organizations (CROs), and others. Pharmaceutical companies accounted for the largest market share of 55.7%, valued at USD 62.35 billion in 2025, driven by substantial investments in research and development, advanced drug discovery infrastructure, and the adoption of emerging technologies such as artificial intelligence, genomics, and bioinformatics. Their extensive financial resources and scientific expertise enable them to manage the complete drug development lifecycle, from target discovery and preclinical research to clinical trials and commercialization.
On the other hand, contract research organizations (CROs) are anticipated to register the fastest CAGR of 10.7% during the forecast period, fueled by the growing trend of outsourcing drug discovery and development activities. Pharmaceutical and biotechnology companies increasingly rely on CROs to reduce development costs, accelerate project timelines, access specialized expertise, and improve operational flexibility.
With continued investments in advanced technologies and strategic collaborations, pharmaceutical companies remain at the forefront of innovation, while the expanding role of CROs is reshaping global drug discovery by delivering faster, more efficient, and cost-effective research services.
Speak to an Analystto discuss market opportunities.
North America dominated the drug discovery market with a 42.5% share in 2025, accounting for USD 47.57 billion, and is projected to grow at a CAGR of 8.9% during the forecast period. The region's growth is driven by a robust pharmaceutical industry, advanced research infrastructure, substantial investments in biotechnology and research and development (R&D), and the presence of leading pharmaceutical and biotechnology companies. Strong regulatory support, extensive clinical research capabilities, and increasing demand for innovative therapies further strengthen the region's leadership.
The U.S. market was valued at USD 42.34 billion in 2025. The country dominates the regional market due to the world's largest pharmaceutical industry, significant R&D spending, advanced drug discovery platforms, and a favorable regulatory environment that accelerates innovation. The presence of major pharmaceutical companies, biotechnology firms, and leading research institutions continues to drive market expansion.
Canada's market reached USD 5.23 billion in 2025. Growing investments in biotechnology research, expanding collaborations with global pharmaceutical companies, increasing focus on personalized medicine, and government funding for life sciences research continue to support the country's market growth.
Europe accounted for 28.3% of the drug discovery market, reaching USD 31.68 billion in 2025, and is expected to register a CAGR of 10.8% during the forecast period. Market growth is supported by strong pharmaceutical manufacturing, increasing biotechnology investments, favorable regulatory frameworks, and continuous innovation in precision medicine and advanced therapeutic development.
Germany's market accounted for USD 8.55 billion in 2025. The country's advanced pharmaceutical sector, world-class research institutions, increasing investments in biotechnology, and leadership in precision medicine continue to strengthen its position as Europe's largest drug discovery market.
The U.K. market was valued at USD 5.70 billion in 2025. Strong academic research, expanding biotechnology startups, increasing clinical research activities, and government initiatives supporting life sciences innovation continue to drive market growth.
Asia-Pacific held 20.7% of the drug discovery market, valued at USD 23.17 billion in 2025, and is projected to grow at a CAGR of 9.9% during the forecast period. Rising pharmaceutical manufacturing, increasing R&D investments, supportive government initiatives, expanding biotechnology industries, and cost-effective drug development capabilities are driving market growth across the region.
China's market reached USD 9.85 billion in 2025. Massive government investments in biotechnology, rapid expansion of pharmaceutical research, increasing collaborations with global pharmaceutical companies, and growing biologics and oncology research continue to accelerate market growth.
Japan's market generated USD 5.56 billion in 2025. Advanced research infrastructure, strong focus on personalized medicine, increasing development of therapies for age-related diseases, and strategic collaborations with global biotechnology companies continue to support market expansion.
Latin America accounted for 5.1% of the drug discovery market, totaling USD 5.71 billion in 2025, and is expected to grow at a CAGR of 7.6% during the forecast period. Increasing pharmaceutical investments, improving healthcare infrastructure, expanding clinical research activities, and rising demand for innovative therapies are supporting regional market growth.
Brazil's market was valued at USD 2.86 billion in 2025. The country's large pharmaceutical industry, growing biotechnology sector, increasing investments in clinical research, and government support for healthcare innovation continue to drive market expansion.
The Middle East & Africa accounted for 3.4% of the drug discovery market, totaling USD 3.81 billion in 2025, and is anticipated to grow at a CAGR of 6.8% during the forecast period. Growth is supported by improving healthcare infrastructure, increasing investments in pharmaceutical research, expanding biotechnology capabilities, and rising government initiatives to strengthen life sciences across the region.
The UAE market was valued at USD 0.95 billion in 2025. Government investments in biotechnology, expanding pharmaceutical research centers, increasing collaborations with international drug developers, and the development of advanced healthcare infrastructure continue to support market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com